Search clinical trials for: modified release formulation of oxcarbazepine (OXC MR)

Total 201 results

Desitin Arzneimittel GmbH
FGK Clinical Research GmbH

Terminated

EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

Partial Epilepsy

Germany
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Healthy

Singapore
Pfizer

Completed

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

Healthy

United States
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

Healthy

Singapore
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Rock Creek Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations

Pharmacokinetics of Anatabine

United Kingdom
Supernus Pharmaceuticals, Inc.

Completed

Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

Epilepsies, Partial

United States
Lung Biotechnology PBC

Completed

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Czechia, Germany, Ireland, Romania
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Lung Biotechnology PBC

Completed

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Ireland
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Collaborative Care Initiative, LLC
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen...

Unknown

Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression

Bipolar Depression | Treatment Effectiveness | Measure-based Guidance

United States
Amgen

Completed

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

Healthy Volunteers

United States
Pfizer

Completed

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

Healthy

United States
Lundquist Institute for Biomedical Innovation at...
Lung Biotechnology PBC

Completed

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States
Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
University of Manchester
King's College London; Northern Care Alliance NHS Foundation Trust; University... and other collaborators

Completed

The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms (BeneMin)

Schizophrenia and Disorders With Psychotic Features
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF (PeACE)

Kidney Transplantation

Korea, Republic of
Sirtris, a GSK Company

Completed

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Psoriasis

United States
Astellas Pharma Inc

Completed

A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients

Liver Transplantation

United States
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Icahn School of Medicine at Mount Sinai
U.S. Department of Education

Completed

Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury

Neuropathic Pain | Spinal Cord Injury

United States
Supernus Pharmaceuticals, Inc.

Approved for marketing

Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

Epilepsy

United States
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

Liver Transplantation

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

Metastatic Melanoma and Merkel Cell Carcinoma

Germany, Switzerland
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients

Liver Transplantation

United States
Velicept Therapeutics, Inc.

Completed

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (VEL-2001)

Overactive Bladder

United States
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

Kidney Transplantation

United States, Canada
University of Colorado, Denver

Withdrawn

Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia

Trigeminal Neuralgia
Supernus Pharmaceuticals, Inc.
Parexel

Completed

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1)

Epilepsies, Partial

United States, Poland, Mexico, Bulgaria, Romania, Canada, Russian Federation, Croatia
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Ian McGowan
National Institute of Allergy and Infectious Diseases (NIAID); CONRAD

Completed

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

HIV Prevention

United States
Abbott
Eilaf

Completed

Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER) (CLOSER)

Respiratory Tract Infection

Egypt, Saudi Arabia
Pfizer

Completed

Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Major Depressive Disorder
Sanofi

Completed

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia

Sleep Initiation and Maintenance Disorders

United States, Canada, Australia
Bial - Portela C S.A.

Completed

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Novartis Pharmaceuticals

Approved for marketing

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (ACCESS)

Acromegaly

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Healthy

United States
OBEcure Ltd.

Completed

Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects

Healthy

Romania
Astellas Pharma China, Inc.

Completed

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

Kidney Transplant

China
Labatec Pharma SA

Unknown

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Osteoporosis, Postmenopausal

Switzerland
Mundipharma Research Limited

Terminated

A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

Polymyalgia Rheumatica

United Kingdom
Université Catholique de Louvain

Unknown

Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism (CYRANO)

Kidney Diseases

Belgium
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial Cancer

United States, Canada, Norway, United Kingdom, Australia
Pfizer

Completed

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

Healthy

United States
Astellas Pharma Inc

Completed

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Major Depressive Disorder

Japan

3

Subscribe